

TG Therapeutics, Inc. (TGTX)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001001316

TG Therapeutics, Inc.	
TGTX; healthcare	
Grade	A A B C D E strongest fifth of 371 graded peers percentile 10.5; sampling error 2.5 points; lower is stronger
Rank	40 of 371
Profitability	C/D percentile 61.3
Solvency	B percentile 29.0
Growth and financing	A percentile 11.5
Reliability	0.91 AUC filers with \$591M to \$2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$591M to \$2.67B assets total assets \$1.1B
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active
Inputs computable	8 of 14
Graded from	filings received through Feb 27, 2026 224 days before the rescans; latest periodic filing 10-Q received Aug 5, 2026
Last close	\$53.33 2026-10-08; market equity \$8.2B
Price used in grade	None



A, the bull

strongest fifth of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescans

split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: D/E from Oct 21, 2023, A/B from Mar 21, 2024, A from Feb 21, 2024

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 27, 2026

TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 61.3						
Gross profitability		48.5%	32.2%	24.3	372	2025-12-31
Return on invested capital		not computable	9.3%			latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Accruals ratio		57.5%	(6.6%)	98.4	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 3
Solvency, sleeve percentile 29.0						
Twelve-month failure probability		0.03%	0.07%	13.8	248	2026-06-30
Altman Z double-prime		2.04	(0.31)	28.7	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Current ratio		4.10x	2.96x	44.4	839	2025-12-31
Growth and financing, sleeve percentile 11.5						
Revenue growth, three-year compound		504.9%	10.0%	0.2	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000 pretax income must exceed the validity floor and imply a 0%-100% tax rate
Reinvestment rate		not computable	37.1%			
Asset growth, three years		76.4%	2.1%	4.1	704	2025-12-31
Net share issuance, one year		1.7%	2.5%	30.0	634	2026-02-25

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
35	Viridian Therapeutics, Inc.\DE (VRDN)	9.2	A	dilution, fortress balance sheet
36	Xtant Medical Holdings, Inc. (XTNT)	9.5	A	fortress balance sheet
37	Viemed Healthcare, Inc. (VMD)	9.7	A	
38	LivaNova plc (LIVN)	10.0	A	fortress balance sheet
39	TransMedics Group, Inc. (TMDX)	10.3	A	
40	TG Therapeutics, Inc. (TGTX) <	10.5	A	
41	Niagen Bioscience, Inc. (NAGE)	10.8	A	
42	BridgeBio Pharma, Inc. (BBIO)	11.1	A	
43	PRO DEX Inc. (PDEX)	11.4	A	
44	Sanara MedTech Inc. (SMTI)	11.6	A	
45	Orthopediatrics Corp. (KIDS)	11.9	A	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	50.3%	8.0%	76
Distance from 52-week high	(9.7%)	(31.4%)	85
EBIT to enterprise value	1.6%	(1.5%)	60
Free cash flow yield	(0.3%)	(1.0%)	52
Book value to price	0.07	0.28	23
Sales to price	0.08	0.31	21
Composite equity issuance, five years	8.5%	20.3%	38
Relative strength against the sector, log excess return	0.20	(0.14)	76

Diagnostics

not in the grade

Measure	Value
Piotroski F-score 4 of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	pass
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$482.6M
Operating cash flow, four quarters	\$17.9M

Months of runway	not finite
Days since last periodic filing	65 (10-Q received Aug 5, 2026)
Median daily dollar volume, 63 sessions	\$92.6M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$616.3M	2025-12-31	2026-02-27	10-K	0001437749-26-006133
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$100.7M	2025-12-31	2026-02-27	10-K	0001437749-26-006133
3	assets	us-gaap:Assets	\$1.1B	2025-12-31	2026-02-27	10-K	0001437749-26-006133
4	operating income	us-gaap:OperatingIncomeLoss	\$20.6M	2023-12-31	2026-02-27	10-K	0001437749-26-006133
5	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$114.1M	2025-12-31	2026-02-27	10-K	0001437749-26-006133
6	income tax	us-gaap:IncomeTaxExpenseBenefit	\$390,000	2023-12-31	2026-02-27	10-K	0001437749-26-006133
7	total debt	us-gaap:LongTermDebt	\$100.4M	2023-12-31	2024-02-29	10-K	0001437749-24-006144
8	book equity	us-gaap:StockholdersEquity	\$160.5M	2023-12-31	2026-02-27	10-K	0001437749-26-006133
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$92.9M	2023-12-31	2026-02-27	10-K	0001437749-26-006133
10	total debt	us-gaap:LongTermDebt	\$71.1M	2022-12-31	2023-03-01	10-K	0001558370-23-002610
11	book equity	us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrolling	\$118.6M	2022-12-31	2023-03-01	10-K	0001558370-23-002610
12	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$102.3M	2022-12-31	2025-03-03	10-K	0001437749-25-005908
13	net income	us-gaap:NetIncomeLoss	\$447.2M	2025-12-31	2026-02-27	10-K	0001437749-26-006133
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$24.8M	2025-12-31	2026-02-27	10-K	0001437749-26-006133
15	assets	us-gaap:Assets	\$577.7M	2024-12-31	2026-02-27	10-K	0001437749-26-006133
16	current assets	us-gaap:AssetsCurrent	\$630.8M	2025-12-31	2026-02-27	10-K	0001437749-26-006133
17	current liabilities	us-gaap:LiabilitiesCurrent	\$153.8M	2025-12-31	2026-02-27	10-K	0001437749-26-006133
18	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$1.1B	2025-12-31	2026-02-27	10-K	0001437749-26-006133
19	operating income	us-gaap:OperatingIncomeLoss	\$123.3M	2025-12-31	2026-02-27	10-K	0001437749-26-006133
20	book equity	us-gaap:StockholdersEquity	\$648.0M	2025-12-31	2026-02-27	10-K	0001437749-26-006133
21	liabilities	us-gaap:Liabilities	\$415.2M	2025-12-31	2026-02-27	10-K	0001437749-26-006133
22	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$211,000	2023-12-31	2026-02-27	10-K	0001437749-26-006133
23	interest expense	us-gaap:InterestExpense	\$12.6M	2023-12-31	2024-02-29	10-K	0001437749-24-006144
24	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$329.0M	2024-12-31	2026-02-27	10-K	0001437749-26-006133
25	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$233.7M	2023-12-31	2026-02-27	10-K	0001437749-26-006133
26	revenue	us-gaap:Revenues	\$2.8M	2022-12-31	2023-03-01	10-K	0001558370-23-002610
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$214,000	2025-12-31	2026-02-27	10-K	0001437749-26-006133
28	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$40.5M	2024-12-31	2026-02-27	10-K	0001437749-26-006133
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$45,000	2024-12-31	2026-02-27	10-K	0001437749-26-006133
30	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$31.4M	2023-12-31	2026-02-27	10-K	0001437749-26-006133
31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$0	2023-12-31	2026-02-27	10-K	0001437749-26-006133
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$176.2M	2022-12-31	2025-03-03	10-K	0001437749-25-005908
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$14,000	2022-12-31	2025-03-03	10-K	0001437749-25-005908
34	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$59,000	2025-12-31	2026-02-27	10-K	0001437749-26-006133
35	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$114.1M	2025-12-31	2026-02-27	10-K	0001437749-26-006133
36	income tax	us-gaap:IncomeTaxExpenseBenefit	-\$339.8M	2025-12-31	2026-02-27	10-K	0001437749-26-006133
37	current assets	us-gaap:AssetsCurrent	\$566.4M	2024-12-31	2026-02-27	10-K	0001437749-26-006133
38	current liabilities	us-gaap:LiabilitiesCurrent	\$90.7M	2024-12-31	2026-02-27	10-K	0001437749-26-006133
39	assets	us-gaap:Assets	\$329.6M	2023-12-31	2025-03-03	10-K	0001437749-25-005908
40	assets	us-gaap:Assets	\$193.6M	2022-12-31	2024-02-29	10-K	0001437749-24-006144
41	shares outstanding	dei:EntityCommonStockSharesOutstanding	159,688,256	2026-02-25	2026-02-27	10-K	0001437749-26-006133
42	shares outstanding	dei:EntityCommonStockSharesOutstanding	157,070,575	2025-02-25	2025-03-03	10-K	0001437749-25-005908